Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 302 Shares of Stock

Posted by Francis Steltz on Nov 4th, 2026

Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider John Fesko sold 302 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $400.01, for a total value of $120,803.02. Following the completion of the transaction, the insider owned 195,276 shares in the company, valued at $78,112,352.76. This trade represents a 0.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

On Wednesday, October 28th, John Fesko sold 898 shares of Natera stock. The shares were sold at an average price of $426.34, for a total value of $382,853.32.
On Tuesday, October 27th, John Fesko sold 781 shares of Natera stock. The shares were sold at an average price of $406.00, for a total value of $317,086.00.
On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01.

Natera Stock Up 0.6%

Shares of Natera stock traded up $2.40 on Wednesday, reaching $391.03. 2,799,993 shares of the company were exchanged, compared to its average volume of 1,672,252. The company’s 50-day moving average is $380.30 and its two-hundred day moving average is $268.64. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41.

Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same period in the prior year, the firm posted ($0.74) earnings per share. The firm’s revenue for the quarter was up 37.7% compared to the same quarter last year. Equities research analysts forecast that Natera, Inc. will post -1.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on NTRA shares. Piper Sandler increased their target price on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Thursday, October 15th. UBS Group increased their price objective on Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. BTIG Research lifted their target price on shares of Natera from $320.00 to $430.00 and gave the company a “buy” rating in a research note on Tuesday, October 27th. Finally, Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Friday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $394.31.

Read Our Latest Report on NTRA

Institutional Trading of Natera

A number of institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Natera during the second quarter valued at about $2,962,770,000. K.J. Harrison & Partners Inc bought a new position in Natera in the 2nd quarter worth approximately $5,117,000. Abbot Financial Management Inc. bought a new stake in shares of Natera in the second quarter valued at approximately $1,537,000. Eagle Health Investments LP acquired a new stake in shares of Natera in the second quarter worth $4,302,000. Finally, BlueCrest Capital Management Ltd acquired a new position in Natera during the 2nd quarter valued at $11,695,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

More Natera News

Here are the key news stories impacting Natera this week:

Positive Sentiment: Medicare coverage for Signatera in HCC could improve patient access and support adoption of Natera’s cancer-monitoring tests. The coverage milestone adds to the commercial opportunity for its oncology business. Natera Medicare coverage for Signatera in HCC
Positive Sentiment: New ESMO oncology evidence was described as broadening the case for Natera’s cancer-testing portfolio, potentially reinforcing the longer-term growth story. ESMO data broaden Natera’s oncology case
Neutral Sentiment: Natera was expected to report earnings on November 5, making results and management’s outlook a near-term catalyst; the preview article did not provide reported results. Natera earnings preview
Neutral Sentiment: The reported analyst consensus price target was $394.31, close to the share price cited in the provided market background, suggesting limited implied upside from that target alone. Natera consensus target price
Neutral Sentiment: CFO Michael Brophy sold 1,178 shares under a pre-arranged Rule 10b5-1 plan and retained 48,480 shares. The scheduled nature and relatively small size of the sale may temper its significance as a signal about management’s outlook. CFO share sale report

About Natera

(Get Free Report)

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.